110 related articles for article (PubMed ID: 29729562)
1. Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.
Goey KKH; Mahmoud R; Sørbye H; Glimelius B; Köhne CH; Sargent DJ; Punt CJA; van Oijen MGH; Koopman M
Eur J Cancer; 2018 Jun; 96():115-124. PubMed ID: 29729562
[TBL] [Abstract][Full Text] [Related]
2. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
Goey KKH; Sørbye H; Glimelius B; Adams RA; André T; Arnold D; Berlin JD; Bodoky G; de Gramont A; Díaz-Rubio E; Eng C; Falcone A; Grothey A; Heinemann V; Hochster HS; Kaplan RS; Kopetz S; Labianca R; Lieu CH; Meropol NJ; Price TJ; Schilsky RL; Schmoll HJ; Shacham-Shmueli E; Shi Q; Sobrero AF; Souglakos J; Van Cutsem E; Zalcberg J; van Oijen MGH; Punt CJA; Koopman M
Eur J Cancer; 2018 Sep; 100():35-45. PubMed ID: 29936065
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification.
Sorbye H; Köhne CH; Sargent DJ; Glimelius B
Ann Oncol; 2007 Oct; 18(10):1666-72. PubMed ID: 17660495
[TBL] [Abstract][Full Text] [Related]
4. Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
Goey KK; 't Lam-Boer J; de Wilt JH; Punt CJ; van Oijen MG; Koopman M
Eur J Cancer; 2016 Dec; 69():166-177. PubMed ID: 27821320
[TBL] [Abstract][Full Text] [Related]
5. Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
Sivendran S; Newport K; Horst M; Albert A; Galsky MD
Trials; 2015 Aug; 16():341. PubMed ID: 26253548
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
[TBL] [Abstract][Full Text] [Related]
7. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
8. Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines.
Watine J; Friedberg B
Clin Chim Acta; 2004 Jul; 345(1-2):1-15. PubMed ID: 15193973
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.
Sorbye H; Pfeiffer P; Cavalli-Björkman N; Qvortrup C; Holsen MH; Wentzel-Larsen T; Glimelius B
Cancer; 2009 Oct; 115(20):4679-87. PubMed ID: 19562777
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making.
Rees JR; Whale K; Fish D; Fayers P; Cafaro V; Pusic A; Blazeby JM; Efficace F
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2181-92. PubMed ID: 25910987
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Effect of Performance Status on Outcomes of Patients with Colorectal Cancer Receiving First-Line Chemotherapy: A Meta-analysis.
Colloca GA; Venturino A
J Gastrointest Cancer; 2024 Mar; 55(1):418-426. PubMed ID: 37966630
[TBL] [Abstract][Full Text] [Related]
13. Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Giessen C; Stintzing S; Laubender RP; Ankerst DP; Schulz C; Moosmann N; Modest DP; Schalhorn A; von Weikersthal LF; Heinemann V
Clin Colorectal Cancer; 2011 Dec; 10(4):317-24. PubMed ID: 21729676
[TBL] [Abstract][Full Text] [Related]
14. A systematic analysis highlighting deficiencies in reported outcomes for patients with stage IV colorectal cancer undergoing palliative resection of the primary tumour.
Harji DP; Vallance A; Selgimann J; Bach S; Mohamed F; Brown J; Fearnhead N
Eur J Surg Oncol; 2018 Oct; 44(10):1469-1478. PubMed ID: 30007475
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.
Jary M; Vernerey D; Lecomte T; Dobi E; Ghiringhelli F; Monnien F; Godet Y; Kim S; Bouché O; Fratte S; Gonçalves A; Leger J; Queiroz L; Adotevi O; Bonnetain F; Borg C
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):603-12. PubMed ID: 25583947
[TBL] [Abstract][Full Text] [Related]
16. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.
Jary M; Lecomte T; Bouché O; Kim S; Dobi E; Queiroz L; Ghiringhelli F; Etienne H; Léger J; Godet Y; Balland J; Lakkis Z; Adotevi O; Bonnetain F; Borg C; Vernerey D
Int J Cancer; 2016 Nov; 139(10):2325-35. PubMed ID: 27472156
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
19. The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value.
Ezeife DA; Parimi S; Cusano ER; Smith MK; Truong TH; Raissouni S; Lin Y; Monzon JG; Li H; Tam VC; Tang PA
J Natl Compr Canc Netw; 2017 Aug; 15(8):1005-1013. PubMed ID: 28784862
[No Abstract] [Full Text] [Related]
20. Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.
Grande R; Natoli C; Ciancola F; Gemma D; Pellegrino A; Pavese I; Garufi C; Di Lauro L; Corsi D; Signorelli D; Sperduti I; Cortese G; Risi E; Morano F; Sergi D; Signorelli C; Ruggeri EM; Zampa G; Russano M; Gamucci T
PLoS One; 2016; 11(7):e0157751. PubMed ID: 27442239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
